Please login to the form below

Not currently logged in
Email:
Password:

oral drug therapies

This page shows the latest oral drug therapies news and features for those working in and with pharma, biotech and healthcare.

Novo Nordisk’s collaboration with MIT and BWH expanded

Novo Nordisk’s collaboration with MIT and BWH expanded

Novo Nordisk has announced that its existing research collaboration in oral drug delivery technologies with the Massachusetts Institute of Technology (MIT) and Brigham and Women’s Hospital (BWH) has been expanded. ... that safely and effectively

Latest news

  • FDA rejects ViiV’s long-acting monthly HIV injection FDA rejects ViiV’s long-acting monthly HIV injection

    In previous trials testing the long-acting treatment, ViiV’s injectable was as effective as a standard three-drug oral regime at suppressing levels of HIV. ... ViiV’s rival Gilead was the first company to bring a single-tablet triple therapy –

  • Tecentriq combo shows promise in triple negative breast cancer Tecentriq combo shows promise in triple negative breast cancer

    Ipatasertib is an oral, targeted drug that binds to all three isoforms of AKT, which blocks the PI3K/AKT signalling pathway and may prevent cancer cell growth and survival. ... Keynote-552 is investigating Keytruda in combination with different

  • GSK, J&J say monthly injection keeps HIV controlled GSK, J&J say monthly injection keeps HIV controlled

    three-drug oral regime at suppressing levels of HIV, according to the studies, which involved more than 1, 000 subjects.ealthcare’s. ... ViiV has been pushing a raft of two-drug oral therapies through the pipeline taken as a single tablet once daily to

  • Spinraza lifts Biogen ahead of Alzheimer’s data Spinraza lifts Biogen ahead of Alzheimer’s data

    time, as rival therapies such as oral liquid drug risdiplam (RG7916) developed by Roche and PTC Therapeutics and a one-off gene therapy from Novartis/Avexis that was filed for approval ... UCB-partnered lupus drug dapirolizumab pegol, anti-CD40L drug,

  • Spinraza keeps Biogen buoyant ahead of Alzheimer’s data Spinraza keeps Biogen buoyant ahead of Alzheimer’s data

    On the company’s results call, analysts asked about potential competition to Spinraza from rival therapies such as oral liquid drug risdiplam (RG7916) developed by Roche and PTC Therapeutics and a ... It’s also working on a follow-up to Spinraza with

More from news
Approximately 1 fully matching, plus 11 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
The Difference Collective

Welcome to the Difference Collective – a healthcare communications team of 80+ talented experts who Deliver Differently. We’re purpose-built around...

Latest intelligence

Our Top 5 Pharma Picks From Cannes Lions
Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....
The Evolving Role of the Sales Rep
The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in...
Measure your omnichannel maturity with our new tool
Try our Omnichannel Maturity Tool to gain tangible advice and an instant analysis of your omnichannel readiness....